Drilldown: Medicines
Medicines > classes 
:
Antidepressant or
Sedative-Hypnotic or
[[:Category:Schedule III controlled substances|Schedule III controlled substance]]
:
Antidepressant or
Sedative-Hypnotic or
[[:Category:Schedule III controlled substances|Schedule III controlled substance]] Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
None (3) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator (15) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist (2) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
None (47) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-0000004B-QINU`"', '"`UNIQ--vote-0000004C-QINU`"', '"`UNIQ--vote-0000004D-QINU`"', '"`UNIQ--vote-0000004E-QINU`"' (1)
starting dose:
preparations:
fda max:
routes:
None (46) ·
buccal (Belbuca for pain) (1) ·
intranasal; rectal and IV reported. (1) ·
IV/IM (Buprenex). Oral swallowed: very low bioavailability due to first-pass; not therapeutic. (1) ·
Oral (3) ·
SC depot (Sublocade) (1) ·
sublingual (1) ·
Sublingual (primary for MOUD) (1) ·
transdermal (Butrans) (1)
onset:
None (46) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) ·
Sublingual analgesic effect 30-60 minutes; MOUD craving suppression within hours; Butrans patch steady-state in 3 days. (1) ·
~20–40 min PO; faster sublingual/intranasal. (1)
duration:
None (46) ·
6–10 h subjective; full pharmacologic effect considerably longer. (1) ·
Chronic daily dosing (1) ·
Long (1) ·
MOUD: 24-72 hours per sublingual dose (long; permits every-other-day or three-times-weekly dosing in stable patients); Butrans patch: 7 days; Sublocade depot: 28+ days; Buprenex IV/IM: 6-8 hours. (1)
halflife:
None (46) ·
Buprenorphine sublingual: 24-42 hours (long, contributes to extended dosing intervals). Norbuprenorphine (active metabolite, weaker mu-agonist): 24-48 hours.'"`UNIQ--ref-0000004F-QINU`"' (1) ·
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) ·
~12 hours (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1)
bioavailability:
None (46) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
Not formally characterized in humans. (1) ·
~30% (sublingual; the primary therapeutic route); ~10-20% (oral swallowed, low due to first-pass); ~50% (buccal Belbuca); transdermal Butrans bypasses first-pass.'"`UNIQ--ref-00000050-QINU`"' (1) ·
~50% (highly variable) (1)
pregnancy:
legal:
Showing below up to 50 results in range #1 to #50.